




The relative strengths and weaknesses of CTI Biopharma CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CTI Biopharma CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 11% points. The greatest weakness of CTI Biopharma CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 158% points.

The company's Economic Capital Ratio, given in the ranking table, is 137%, being 108% points below the market average of 245%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	55,824	Assets	63,843
Cost of Goods Sold	0	Liabilities	56,086
Intangible Assets	0	Expenses	106,567
Liabilities, Current	40,646	Revenues	57,405
Liabilities, Non-Current	14,926	Stockholders Equity	7,757
Other Assets	4,996	Net Income	-52,953
Other Compr. Net Income	1,241	Comprehensive Net Income	-52,332
Other Expenses	-3,700	BaseVar	144,466
Other Liabilities	514	ECR before LimitedLiability	-59%
Other Net Income	-3,791	Economic Capital Ratio	137%
Other Revenues	57,405		
Property and Equipment	3,023		
Research and Development	64,961		
Selling, General and Administrative Expense	45,306		